Ken Getz of Tufts CSDD Discusses RBQM Study Conducted with CluePoints and PwC

In part 1 of this video interview series with Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints, Getz touches on the findings from a recent study on RBQM adoption.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Blog

The Hidden Inspection Risk in Your Medical and Safety Review Workflow

You have just been told an inspection is coming. Your team’s first reaction is not to...

Blog

Why Medical and Safety Review Is One of the Last Manual Workflows in Clinical Trials

It is Tuesday morning. You have a data cut from last night, three studies to review...

Blog

Turning Oversight into Evidence: How to Prove Your Decisions at Any Point in a Trial

Clinical trial oversight is changing. For years, Sponsors have focused on demonstrating that oversight activities occurred:...